AR114237A1 - Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico - Google Patents
Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéuticoInfo
- Publication number
- AR114237A1 AR114237A1 ARP190100202A ARP190100202A AR114237A1 AR 114237 A1 AR114237 A1 AR 114237A1 AR P190100202 A ARP190100202 A AR P190100202A AR P190100202 A ARP190100202 A AR P190100202A AR 114237 A1 AR114237 A1 AR 114237A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- nitrogen atom
- group
- atom
- Prior art date
Links
- 229910052757 nitrogen Inorganic materials 0.000 title abstract 9
- -1 AMIDE COMPOUND Chemical class 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 101100463130 Arabidopsis thaliana PDK gene Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 208000012268 mitochondrial disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente proporciona un compuesto que tiene actividad inhibitoria de PDHK y útil para el tratamiento o profilaxis de diabetes (diabetes tipo 1, diabetes tipo 2, etc.), síndrome de resistencia a la insulina, síndrome metabólico, hiperglucemia, hiperlactacidemia, complicación diabéticas (neuropatía diabética, retinopatía diabética, nefropatía diabética, catarata etc.), insuficiencia cardíaca (insuficiencia cardíaca aguda, insuficiencia cardíaca crónica), cardiomiopatía, isquemia miocárdica, infarto de miocardio, angina de pecho, dislipidemia, aterosclerosis, enfermedad arterial periférica, claudicación intermitente, enfermedad pulmonar obstructiva crónica, isquemia cerebral, apoplejía cerebral, enfermedad mitocondrial, encefalomiopatía mitocondrial, cáncer, hipertensión pulmonar o enfermedad de Alzheimer. La presente se refiere a un compuesto de la fórmula [1] o la fórmula [2], o una de sus sales farmacéuticamente aceptables, donde cada símbolo significa lo mismo como se describe en la memoria descriptiva. Reivindicación 1: Un compuesto de la fórmula [1] o la fórmula [2], o una de sus sales farmacéuticamente aceptables, caracterizado porque un enlace en una línea de puntos es un enlace simple o un enlace doble; X¹ es un átomo de carbono, un átomo de nitrógeno o un átomo de oxígeno; X² es un átomo de carbono o un átomo de nitrógeno; R¹ᵃ es alquilo C₁₋₄ o alquilo C₁₋₄carbonilo; R² es halógeno, ciano o alquilo C₁₋₄; m es 0 ó 1; n es 0, 1 ó 2, cuando n es 2, cada R² es el mismo o diferente; A¹, A², A³, A⁴, A⁵, A⁶ y A⁷ se seleccionan de modo independiente de un átomo de carbono, un átomo de nitrógeno y un átomo de oxígeno; A⁸ se selecciona de un átomo de carbono y un átomo de nitrógeno, y un número total del átomo de nitrógeno y el átomo de oxígeno contenido en una fórmula estructural parcial [3] es 0, 1, 2 ó 3; t es 0 ó 1; r es 0, 1 ó 2, y un total de t y r es 1 ó 2; w es 0 ó 1; R³ y R⁴ son cada uno de modo independiente hidrógeno o alquilo C₁₋₄; Cy¹ es (1) (i) cicloalquilo C₄₋₆; o (ii) heterociclilo saturado o parcialmente saturado de 4 a 6 miembros que tiene un átomo de nitrógeno, el cicloalquilo C₄₋₆ y el heterociclilo saturado o parcialmente saturado está opcionalmente sustituido con un sustituyente seleccionado de modo independiente del grupo que consiste en alquilo C₁₋₄ y oxo, o (2) (i) fenilo o (ii) heteroarilo de 5 ó 6 miembros que tiene 1, 2 ó 3 heteroátomos seleccionados de modo independiente del grupo que consiste en un átomo de nitrógeno y un átomo de oxígeno, el fenilo y el heteroarilo están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, ciano, carboxi, alquilo C₁₋₄, haloalquilo C₁₋₄ y cicloalquilo C₃₋₆; Cy² es (1) (i) cicloalquilo C₃₋₆ o (ii) heterociclilo saturado de 4 a 6 miembros que tiene 1 ó 2 heteroátomos seleccionados de modo independiente del grupo que consiste en un átomo de nitrógeno y un átomo de oxígeno, y el cicloalquilo C₃₋₆ y el heterociclilo saturado están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, hidroxi y alquilo C₁₋₄, o (2) (i) fenilo o (ii) heteroarilo de 5 ó 6 miembros que tiene 1, 2, 3 ó 4 átomos de nitrógeno, y el fenilo y el heteroarilo están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, ciano, alquilo C₁₋₄, alcoxi C₁₋₄; y alquilo C₁₋₄sulfonilo; y v es 0 ó 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114237A1 true AR114237A1 (es) | 2020-08-05 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100202A AR114237A1 (es) | 2018-02-01 | 2019-01-30 | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10800784B2 (es) |
| EP (1) | EP3747888A4 (es) |
| JP (3) | JP7241556B2 (es) |
| KR (1) | KR102725118B1 (es) |
| CN (1) | CN111655692B (es) |
| AR (1) | AR114237A1 (es) |
| AU (1) | AU2019214048B2 (es) |
| BR (1) | BR112020014177A2 (es) |
| CA (1) | CA3090219A1 (es) |
| CL (1) | CL2020002003A1 (es) |
| CO (1) | CO2020009420A2 (es) |
| IL (1) | IL276386B2 (es) |
| MX (1) | MX2020008126A (es) |
| MY (1) | MY205011A (es) |
| PE (1) | PE20211273A1 (es) |
| PH (1) | PH12020500613A1 (es) |
| SA (1) | SA520412473B1 (es) |
| SG (1) | SG11202006916SA (es) |
| TW (1) | TWI803570B (es) |
| WO (1) | WO2019151274A1 (es) |
| ZA (1) | ZA202004548B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020054734A1 (ja) | 2018-09-11 | 2020-03-19 | 日本たばこ産業株式会社 | ピラゾール－アミド化合物を含有する慢性腎臓病の治療又は予防剤 |
| WO2023032940A1 (ja) | 2021-09-01 | 2023-03-09 | 日本たばこ産業株式会社 | 含窒素三環性化合物及びその医薬用途 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| SMT202400344T1 (it) | 2020-02-07 | 2024-11-15 | Gasherbrum Bio Inc | Agonisti di glp-1 eterociclici |
| HRP20251364T1 (hr) * | 2020-03-04 | 2025-12-19 | Japan Tobacco Inc. | Kondenzirani triciklički spoj i njegova medicinska upotreba |
| EP4211139A4 (en) * | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| EP4317144A4 (en) * | 2021-03-23 | 2025-07-23 | Shanghai Haiyan Pharmaceutical Tech Co Ltd | HETEROCYCLE-SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| US8580956B2 (en) * | 2007-06-01 | 2013-11-12 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| JP6147737B2 (ja) * | 2011-06-27 | 2017-06-14 | アレクトス・セラピューティクス・インコーポレイテッド | 選択的グリコシダーゼ阻害剤およびその使用 |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| KR101535954B1 (ko) * | 2012-06-12 | 2015-07-10 | 주식회사 종근당 | Ｇｐｒ１１９ 활성의 효능제로서의 피페리딘 유도체 |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| RS57188B1 (sr) * | 2013-03-15 | 2018-07-31 | Japan Tobacco Inc | Jedinjenje pirazol-amida i njegove medicinske upotrebe |
| JP2015028009A (ja) * | 2013-07-01 | 2015-02-12 | 日本たばこ産業株式会社 | ピラゾール−アルコール化合物およびその医薬用途 |
| WO2015002118A1 (ja) * | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | フルオレン－アミド化合物およびその医薬用途 |
| GB201316823D0 (en) * | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CA2933927C (en) * | 2013-12-17 | 2021-11-16 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| CA2994027C (en) | 2015-07-31 | 2023-10-10 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| EP3436443B1 (en) | 2016-03-29 | 2020-03-11 | Merck Patent GmbH | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| AU2017258697B2 (en) * | 2016-04-28 | 2021-04-15 | Merck Patent Gmbh | Piperidinyl derivatives |
| CA3031621A1 (en) * | 2016-07-29 | 2018-02-01 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
| EP3496716B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| WO2023032940A1 (ja) * | 2021-09-01 | 2023-03-09 | 日本たばこ産業株式会社 | 含窒素三環性化合物及びその医薬用途 |
| HRP20251364T1 (hr) * | 2020-03-04 | 2025-12-19 | Japan Tobacco Inc. | Kondenzirani triciklički spoj i njegova medicinska upotreba |
-
2019
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja not_active Ceased
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114237A1 (es) | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR120183A1 (es) | Compuestos de heteroaril-pirazina como plaguicidas | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20130010A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih | |
| PE20200724A1 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| AR108745A1 (es) | Derivados de oxadiazol microbiocidas | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR069517A1 (es) | Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| AR092202A1 (es) | Derivados de azabencimidazoltetrahidrofurano utiles como activadores de la proteina cinasa activada por amp | |
| AR064824A1 (es) | Derivados de espirocromanona sustituidos | |
| PE20161064A1 (es) | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| AR106047A1 (es) | Derivado de biarilo y medicamento que contiene el mismo para el tratamiento de infecciones fúngicas | |
| AR106778A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo | |
| AR092869A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| AR118706A2 (es) | Compuesto para el control de plagas y vegetación no deseada, procedimiento para prepararlo, composición que lo comprende, y compuesto intermediario relacionado | |
| AR080056A1 (es) | Derivados de ciclohexil-amida como antagonistas de los receptores de crf | |
| AR111199A1 (es) | Compuesto aromático agonista de gpr40 | |
| PE20171443A1 (es) | Derivados de carboxamida | |
| BR112012017474A2 (pt) | composto, sal farmacologicamente aceitável do composto, droga farmacêutica, inibidor da fibrinólise ativável por trombina, promotor da fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, uso de uma composição farmacêutica, inibidor de tafia para injeção, e, uso de uma composição farmacêutica | |
| MY169179A (en) | Novel piperidine compound or salt thereof |